Skip to main content
main-content
Erschienen in: InFo Hämatologie + Onkologie 9/2021

22.09.2021 | Szintigrafie | Zertifizierte Fortbildung

Definition, Staging und Therapie

Das lokal fortgeschrittene Prostatakarzinom*

verfasst von: Dr. med. Florian Girtner, Prof. Dr. med. Maximilian Burger, Priv.-Doz. Dr. med. Johannes Bründl

Erschienen in: InFo Hämatologie + Onkologie | Ausgabe 9/2021

Einloggen, um Zugang zu erhalten

Auszug

Das lokal fortgeschrittene Prostatakarzinom ist auch für erfahrene Behandler anspruchsvoll. In diesem Übersichtsartikel wollen wir die aktuellen Standards zu Risikostratifizierung und Staging sowie den sich derzeit bietenden Therapieoptionen zusammenfassen.
Literatur
4.
Zurück zum Zitat Brierlley G et al (Hrsg). TNM classification of malignant tumours. Hoboken, New Jersey, USA: Wiley-Blackwell, 2017 Brierlley G et al (Hrsg). TNM classification of malignant tumours. Hoboken, New Jersey, USA: Wiley-Blackwell, 2017
5.
Zurück zum Zitat Solyanik O et al. Bildgebung des lokal fortgeschrittenen Prostatakarzinoms. Urologe A. 2017;56(11):1383-93 Solyanik O et al. Bildgebung des lokal fortgeschrittenen Prostatakarzinoms. Urologe A. 2017;56(11):1383-93
6.
Zurück zum Zitat Lee H et al. Accuracy of preoperative multiparametric magnetic resonance imaging for prediction of unfavorable pathology in patients with localized prostate cancer undergoing radical prostatectomy. World J Urol. 2017;35(6):929-34 Lee H et al. Accuracy of preoperative multiparametric magnetic resonance imaging for prediction of unfavorable pathology in patients with localized prostate cancer undergoing radical prostatectomy. World J Urol. 2017;35(6):929-34
7.
Zurück zum Zitat Pompe RS et al. Oncological and functional outcomes after radical prostatectomy for high or very high risk prostate cancer: European validation of the current NCCN® guideline. J Urol. 2017;198(2):354-61 Pompe RS et al. Oncological and functional outcomes after radical prostatectomy for high or very high risk prostate cancer: European validation of the current NCCN® guideline. J Urol. 2017;198(2):354-61
9.
Zurück zum Zitat Akre O et al. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden. Eur Urol. 2011;60(3):554-63 Akre O et al. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden. Eur Urol. 2011;60(3):554-63
10.
Zurück zum Zitat Boorjian SA et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer. 2011;117(13): 2883-91 Boorjian SA et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer. 2011;117(13): 2883-91
11.
Zurück zum Zitat Sooriakumaran P et al. Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ. 2014;348:g1502 Sooriakumaran P et al. Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ. 2014;348:g1502
12.
Zurück zum Zitat Hager B et al. Increasing use of radical prostatectomy for locally advanced prostate cancer in the USA and Germany: a comparative population-based study. Prostate Cancer Prostatic Dis. 2017;20(1):61-6 Hager B et al. Increasing use of radical prostatectomy for locally advanced prostate cancer in the USA and Germany: a comparative population-based study. Prostate Cancer Prostatic Dis. 2017;20(1):61-6
13.
Zurück zum Zitat Ward JF et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int. 2005;95(6):751-56 Ward JF et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int. 2005;95(6):751-56
14.
Zurück zum Zitat Walz J et al. Pathological Results and Rates of Treatment Failure in High-Risk Prostate Cancer Patients After Radical Prostatectomy. BJU Int. 2011;107(5):765-70 Walz J et al. Pathological Results and Rates of Treatment Failure in High-Risk Prostate Cancer Patients After Radical Prostatectomy. BJU Int. 2011;107(5):765-70
15.
Zurück zum Zitat Amling C et al. Primary Surgical Therapy for Clinical Stage T3 Adenocarcinoma of the Prostate. Semin Urol Oncol. 1997;15(4):215-21 Amling C et al. Primary Surgical Therapy for Clinical Stage T3 Adenocarcinoma of the Prostate. Semin Urol Oncol. 1997;15(4):215-21
16.
Zurück zum Zitat Carver B. et al. Long-Term Outcome Following Radical Prostatectomy in Men with Clinical Stage T3 Prostate Cancer. J Urol. 2006;176(2):564-8 Carver B. et al. Long-Term Outcome Following Radical Prostatectomy in Men with Clinical Stage T3 Prostate Cancer. J Urol. 2006;176(2):564-8
17.
Zurück zum Zitat Hsu C et al. Outcome of Surgery for Clinical Unilateral T3a Prostate Cancer: A Single-Institution Experience. Eur Urol. 2007; 51(1):121-8 Hsu C et al. Outcome of Surgery for Clinical Unilateral T3a Prostate Cancer: A Single-Institution Experience. Eur Urol. 2007; 51(1):121-8
18.
Zurück zum Zitat Sciarra A et al. Role of Radical Retropubic Prostatectomy in Patients with Locally Advanced Prostate Cancer: The Influence of Gleason Score 8-10. Urol Int. 2003;70(3):186-94 Sciarra A et al. Role of Radical Retropubic Prostatectomy in Patients with Locally Advanced Prostate Cancer: The Influence of Gleason Score 8-10. Urol Int. 2003;70(3):186-94
19.
Zurück zum Zitat Mazzone et al. Technical Refinements in Superextended Robot-assisted Radical Prostatectomy for Locally Advanced Prostate Cancer Patients at Multiparametric Resonance Imaging. Eur Urol. 2021;80(1):104-112 Mazzone et al. Technical Refinements in Superextended Robot-assisted Radical Prostatectomy for Locally Advanced Prostate Cancer Patients at Multiparametric Resonance Imaging. Eur Urol. 2021;80(1):104-112
20.
Zurück zum Zitat Tewari A et al. Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy. Eur Urol. 2012;62(1):1-15 Tewari A et al. Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy. Eur Urol. 2012;62(1):1-15
21.
Zurück zum Zitat Ham W et al. Robotic radical prostatectomy for patients with locally advanced prostate cancer is feasible: results of a singleinstitution study. J Laparoendosc Adv Surg Tech A. 2009;19(3):329-32 Ham W et al. Robotic radical prostatectomy for patients with locally advanced prostate cancer is feasible: results of a singleinstitution study. J Laparoendosc Adv Surg Tech A. 2009;19(3):329-32
22.
Zurück zum Zitat Nyberg M et al. Functional and Oncologic Outcomes Between Open and Robotic Radical Prostatectomy at 24-month Follow-up in the Swedish LAPPRO Trial. Eur Urol Oncol. 2018;1(5):353-60 Nyberg M et al. Functional and Oncologic Outcomes Between Open and Robotic Radical Prostatectomy at 24-month Follow-up in the Swedish LAPPRO Trial. Eur Urol Oncol. 2018;1(5):353-60
23.
Zurück zum Zitat Menon M et al. Biochemical Recurrence Following Robot-Assisted Radical Prostatectomy: Analysis of 1384 Patients with a Median 5-Year Follow-up. Eur Urol. 2010;58(6):838-46 Menon M et al. Biochemical Recurrence Following Robot-Assisted Radical Prostatectomy: Analysis of 1384 Patients with a Median 5-Year Follow-up. Eur Urol. 2010;58(6):838-46
24.
Zurück zum Zitat Mandel P et al. Incidence, Risk Factors, Management, and Complications of Rectal Injuries During Radical Prostatectomy. Eur Urol Focus. 2018;4(4):554-7 Mandel P et al. Incidence, Risk Factors, Management, and Complications of Rectal Injuries During Radical Prostatectomy. Eur Urol Focus. 2018;4(4):554-7
25.
Zurück zum Zitat Xia L et al. Associations between Hospital Volume and Outcomes of Robot-Assisted Radical Prostatectomy. J Urol. 2020;203(5):926-32 Xia L et al. Associations between Hospital Volume and Outcomes of Robot-Assisted Radical Prostatectomy. J Urol. 2020;203(5):926-32
26.
Zurück zum Zitat Beyer B et al. A feasible and time-efficient adaption of NeuroSAFE for da Vinci robotassisted radical prostatectomy. Eur Urol. 2014;66(1):138-44 Beyer B et al. A feasible and time-efficient adaption of NeuroSAFE for da Vinci robotassisted radical prostatectomy. Eur Urol. 2014;66(1):138-44
27.
Zurück zum Zitat Schlomm T et al. Neurovascular structureadjacent frozen-section examination (NeuroSAFE) increases nerve-sparing frequency and reduces positive surgical margins in open and robot-assisted laparoscopic radical prostatectomy: experience after 11,069 consecutive patients. Eur Urol. 2012;62(2):333-40 Schlomm T et al. Neurovascular structureadjacent frozen-section examination (NeuroSAFE) increases nerve-sparing frequency and reduces positive surgical margins in open and robot-assisted laparoscopic radical prostatectomy: experience after 11,069 consecutive patients. Eur Urol. 2012;62(2):333-40
28.
Zurück zum Zitat Bader P et al. Disease Progression and Survival of Patients with Positive Lymph Nodes After Radical Prostatectomy. Is There a Chance of Cure? J Urol. 2003; 169(3):849-54 Bader P et al. Disease Progression and Survival of Patients with Positive Lymph Nodes After Radical Prostatectomy. Is There a Chance of Cure? J Urol. 2003; 169(3):849-54
29.
Zurück zum Zitat Fossati N et al. The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. Eur Urol. 2017;72(1):84-109 Fossati N et al. The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. Eur Urol. 2017;72(1):84-109
30.
Zurück zum Zitat Rexer H et al. Operative Studie zur Ausdehnung der Lymphadenektomie beim Intermediate- und High-risk-Prostatakarzinom. Forum. 2021;36(1)76-8 Rexer H et al. Operative Studie zur Ausdehnung der Lymphadenektomie beim Intermediate- und High-risk-Prostatakarzinom. Forum. 2021;36(1)76-8
31.
Zurück zum Zitat Van der Poel H et al. Sequential treatment for recurrent localized prostate cancer. J Surg Oncol. 2008;97(5):377-82 Van der Poel H et al. Sequential treatment for recurrent localized prostate cancer. J Surg Oncol. 2008;97(5):377-82
32.
Zurück zum Zitat Widmark A et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomized phase III trial. Lancet. 2009;373(9660):301-8 Widmark A et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomized phase III trial. Lancet. 2009;373(9660):301-8
33.
Zurück zum Zitat Akakura K et al. A Randomized Trial Comparing Radical Prostatectomy Plus Endocrine Therapy Versus External Beam Radiotherapy Plus Endocrine Therapy for Locally Advanced Prostate Cancer: Results at Median Follow-up of 102 Month. Jpn J Clin Oncol. 2006;36(12):789-93 Akakura K et al. A Randomized Trial Comparing Radical Prostatectomy Plus Endocrine Therapy Versus External Beam Radiotherapy Plus Endocrine Therapy for Locally Advanced Prostate Cancer: Results at Median Follow-up of 102 Month. Jpn J Clin Oncol. 2006;36(12):789-93
34.
Zurück zum Zitat Saito T et al. Outcomes of Locally Advanced Prostate Cancer: A Single Institution Study of 209 Patients in Japan. Asian J Androl. 2006;8(5):555-61 Saito T et al. Outcomes of Locally Advanced Prostate Cancer: A Single Institution Study of 209 Patients in Japan. Asian J Androl. 2006;8(5):555-61
35.
Zurück zum Zitat Edamura K et al. Long-Term Clinical Outcomes of 420 Consecutive Prostate Cancer Patients in a Single Institute. Acta Med Okayama. 2005;59(5):195-9 Edamura K et al. Long-Term Clinical Outcomes of 420 Consecutive Prostate Cancer Patients in a Single Institute. Acta Med Okayama. 2005;59(5):195-9
36.
Zurück zum Zitat Mandel P et al. Radikale Prostatektomie beim klinisch lokal fortgeschrittenen Prostatakarzinom. Urologe A. 2017;56(11):1394-401 Mandel P et al. Radikale Prostatektomie beim klinisch lokal fortgeschrittenen Prostatakarzinom. Urologe A. 2017;56(11):1394-401
37.
Zurück zum Zitat Berglund R et al. Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109. Urology. 2012;79(3):633-7 Berglund R et al. Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109. Urology. 2012;79(3):633-7
38.
Zurück zum Zitat Eastham J et al. Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. J Clin Oncol. 2020;38(26):3042-50 Eastham J et al. Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. J Clin Oncol. 2020;38(26):3042-50
Metadaten
Titel
Definition, Staging und Therapie
Das lokal fortgeschrittene Prostatakarzinom*
verfasst von
Dr. med. Florian Girtner
Prof. Dr. med. Maximilian Burger
Priv.-Doz. Dr. med. Johannes Bründl
Publikationsdatum
22.09.2021
Verlag
Springer Medizin
Erschienen in
InFo Hämatologie + Onkologie / Ausgabe 9/2021
Print ISSN: 2662-1754
Elektronische ISSN: 2662-1762
DOI
https://doi.org/10.1007/s15004-021-8775-7

Weitere Artikel der Ausgabe 9/2021

InFo Hämatologie + Onkologie 9/2021 Zur Ausgabe

Neues aus der Forschung

Gute Nachricht für Krebspatienten

Passend zum Thema

DKK 2022

Dossier zum Deutschen Krebskongress

Im CityCube Berlin dreht sich vom 13. bis 16. November 2022 alles um die Krebsmedizin: „Schnittstellen zwischen Innovation und Versorgung“ lautet das Motto des 35. Deutschen Krebskongresses (DKK). Wir berichten tagesaktuell von der größten onkologischen Fachtagung in Deutschland. News, Interviews, Diskussionen und Veranstaltungshinweise sammelt unser Kongressdossier.

Eine Kooperation von Springer Medizin mit der Deutschen Krebsgesellschaft und der Deutschen Krebshilfe.

Mehr